Zota Healthcare Quarterly Results
Zota Healthcare quarterly results. In Mar 2026, Zota Healthcare (ZOTA) reported revenue ₹166 Cr and net profit ₹-15 Cr — revenue +69.4% YoY. Review ZOTA earnings multiple to evaluate earnings-based valuation against sector peers.
ZOTA Quarterly Results — Revenue, Profit & EPS Highlights
Zota Healthcare latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. Check ZOTA company valuation to track the company's total market size over time.
- Revenue of ₹166 Cr in Mar 2026 (-5.7% vs Jun 2026, +69.4% vs Mar 2025)
- Net Profit of ₹-15 Cr in Mar 2026 (+65.9% vs Jun 2026, -15.4% vs Mar 2025)
- EBITDA of ₹6 Cr in Mar 2026 (+160.0% vs Jun 2026)
- Operating Margin of 2.0% in Mar 2026 (+9.0pp vs Jun 2026)
- Earnings Per Share of ₹-4.13 in Mar 2026 (+67.2% vs Jun 2026)
Zota Healthcare Quarterly Results — Revenue, EBITDA, Net Profit & EPS
ZOTA quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Mar 2026 | Jun 2026 | Sept 2025 | Mar 2025 | Jun 2025 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 166 | 176 | 131 | 98 | 105 | -5.7% | 69.4% |
| Net Profit (₹ Cr) | -15 | -44 | -16 | -13 | -14 | - | - |
| EBITDA (₹ Cr) | 6 | -10 | 8 | 4 | 5 | - | - |
| EPS (₹) | -4.13 | -12.58 | -5.26 | -4.57 | -4.92 | - | - |
| Operating Margin (%) | 2.0% | -7.0% | 5.0% | 3.0% | 4.0% | - | - |
ZOTA Share Price Trend — 1-Year Movement Across Quarterly Results
Zota Healthcare 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. For annual financials, live price and key ratios, visit ZOTA share price screener.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
ZOTA vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Zota Healthcare latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Mar 2026 |
₹432,120.23 Cr | 1779.7 | 15,018 | 2,710 | -5.6% | - | 18.0% | 157.5 |
|
Divis Laboratories
Mar 2026 |
₹244,124.91 Cr | 9196.0 | 2,986 | 751 | -5.0% | - | 25.2% | 324.8 |
|
Torrent Pharmaceuti…
Mar 2026 |
₹188,719.51 Cr | 4772.0 | 4,111 | 364 | +27.7% | +42.2% | 8.9% | 414.6 |
|
Zydus Life Science
Mar 2026 |
₹113,615.69 Cr | 1139.0 | 7,569 | 1,341 | -4.3% | - | 17.7% | 90.0 |
|
Cipla
Mar 2026 |
₹108,576.18 Cr | 1335.5 | 6,612 | 543 | -9.3% | - | 8.2% | 194.4 |
QoQ: Quarter over Quarter • YoY: Year over Year
All amounts in ₹ Crores